Document:

QuickLinks
 -- Click here to rapidly navigate through this document

Exhibit 4.2  

 
 

[FORM OF STOCK CERTIFICATE]    

THIS
CERTIFICATE IS TRANSFERABLE

IN CANTON, MA, JERSEY CITY, NJ

AND NEW YORK CITY, NY 

INCORPORATED
UNDER THE LAWS

OF THE STATE OF DELAWARE 

8.75%
SERIES E CUMULATIVE REDEEMABLE PREFERRED STOCK

PAR VALUE $.01 PER SHARE

(LIQUIDATION PREFERENCE $25.00 PER SHARE) 

CUSIP
#601148 40 6 

SEE
REVERSE FOR CERTAIN RESTRICTIONS

AND DEFINITIONS 

[LOGO
OF THE MILLS CORPORATION] 

THE
MILLS CORPORATION 

This
Certifies that
                                         
                                          
              

is
the owner of                                       

fully
paid and non-assessable shares of the 8.75% Series E Cumulative Redeemable Preferred Stock of The Mills Corporation (hereinafter referred to as the "Corporation"),
transferable on the books of the Corporation by the holder hereof in person or by duly authorized attorney upon of the surrender of this Certificate properly endorsed and subject to the restrictions
on transfer noted on the reverse hereof. This Certificate and the shares which it represents are issued and are and shall be subject to all the provisions of the Amended and Restated Certificate of
Incorporation of the Corporation, a copy of which is on file with the Transfer Agent, to all of which the holder of this Certificate assents by acceptance hereof. 

This
Certificate is not valid unless countersigned by the Transfer Agent and registered by the Registrar. 

Witness
the seal of the Corporation and the signatures of its duly authorized officers. 

Dated:

	/s/ Thomas E. Frost
 Secretary	 	/s/ Laurence C. Siegel
 Chairman and Chief Executive Officer	 	Countersigned and Registered: EquiServe Trust Company, N.A., Transfer Agent and Registrar
	

 	
 	

 	
 	

By:	
 	

 
	 	 	 	 	 	 	

	

 	
 	

 	
 	

Authorized Signature

[FORM
OF REVERSE OF CERTIFICATE] 

THE
MILLS CORPORATION 

The
shares represented by this certificate are subject to restrictions on transfer for the purpose of the Corporation's maintenance of its status as a Real Estate Investment Trust under the Internal
Revenue Code of 1986, as amended. Except as otherwise provided by the Corporation's Amended and Restate Certificate of Incorporation, no Person may Beneficially Own shares of capital stock in excess
of 5% (or such greater percentage as may be determined by the Board of Directors of the Corporation) in value of the outstanding capital stock of the Corporation (unless such Person is an Existing
Holder). Separate restrictions regarding Existing Holders are set forth in Article XII of the Amended and Restated Certificate of Incorporation of the Corporation. Any Person who attempt to
Beneficially Own shares of capital stock in excess of the above limitations must immediately notify the Corporation. Any such Person who is a stockholder of record or a Beneficial Owner of capital
stock and each Person who is holding capital stock for a Beneficial Owner, as defined in Article XII of the Amended and Restated Certificate of Incorporation of the Corporation, shall provide
to the Corporation written notice as required by Article XII of the Amended and Restated Certificate of Incorporation of the Corporation. Any shares of capital stock so held may be subject to
mandatory redemption or sale in certain events, and certain purported acquisitions of Beneficial Ownership of shares of capital stock in excess of such limitations shall be void ab initio and shall
result in the automatic exchange of the shares of capital stock represented hereby for shares of Excess Stock which shall be held in trust by the Corporation. A Person who attempts to Beneficially Own
shares in violation of the ownership provisions set forth in Section 12.2 of the Corporation's Amended and Restated Certificate of Incorporation shall have no claim, cause of action or any
other recourse whatsoever against a transfer of such shares. All capitalized terms in this legend have the meaning set forth in the Corporation's Amended and Restated
Certificate of Incorporation, a copy of which, including the restrictions on transfer, will be sent without charge to each stockholder who so requests. 

The
Corporation is authorized to issue 20 million shares of Preferred Stock, which may be issued in one or more series with such terms as the Board of Directors may determine. The Corporation
will furnish to any stockholder without charge, upon request to any Transfer Agent named on the face of this certificate, a full statement of the powers, designations, preferences and relative,
participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights, and the authority of the
Board of Directors to fix and determine the designations, voting rights and preferences, limitations and special rights of the classes and series of shares of the Corporation. 

        The
following abbreviations, when used in the inscription on the face of this certificate, shall be construed as though they were written out in full according to applicable laws or
regulations: 

	TEN COM	 	—	 	as tenants in common	 	UNIF GIFT MIN ACT —	 	                Custodian                
	TEN ENT	 	—	 	as tenants by the entireties	 	 	 	(Cust.)                        (Minor)
	JT TEN	 	—	 	as joint tenants with right	 	 	 	under Uniform Gifts to Minors
	 	 	 	 	of survivorship and not as	 	 	 	Act                                       
 
	 	 	 	 	tenants in common	 	 	 	                                (State)

        Additional abbreviations may also be used though not in the above list. 

For
Value Received,
                                         
        hereby sell, assign and transfer unto 

PLEASE
INSERT SOCIAL SECURITY OR OTHER

IDENTIFYING NUMBER OF ASSIGNEE 

(PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS INCLUDING ZIP CODE OF ASSIGNEE) 

shares
of the capital stock represented by the within Certificate, and do hereby irrevocably constitute and appoint
                                        
Attorney to transfer the said stock on
the books of the within named Corporation with full power of substitution in the premises. 

	Dated	 	 	 	X	 	 
	 	 	
	 	 	 	

	

 	
 	

 	
 	

X	
 	

	 	 	 	 	NOTICE: The signature to this assignment must correspond with the name as written upon the face of the Certificate in every particular, without alteration or enlargement or any change whatever.

	

SIGNATURE(S) GUARANTEED:	
 	

X	
 	

 
	 	 	 	 	

	 	 	The signature(s) should be guaranteed by an eligible guarantor institution (banks, stockbrokers, savings and loan associations and credit unions with membership in an approved signature guarantee medallion program),
pursuant to S.E.C. Rule 17Ad-15.

QuickLinks

[FORM OF STOCK CERTIFICATE]QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.211    
    

REDACTED VERSION  

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN

OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH

RESPECT TO THE OMITTED PORTIONS.  

December 20,
2002 

Mr. Lutz
Lingnau

President and Chief Executive Officer

Schering Berlin Inc.

340 Changebridge Road

P.O. Box 1000

Montville, NJ 07045-1000

Fax: 973.487.2005 

	Re:
	Regulatory
Filing, Development and Supply Agreement dated May 10, 1993

between Chiron Corporation and Schering AG (the "RFDS Agreement") 

Dear
Lutz: 

This
is to confirm our understanding with respect to cost-sharing for the diluent syringe: 

Chiron
and Schering have agreed to proceed with a diluent syringe for Betaseron®. In connection therewith, Chiron has negotiated agreements with Baxter for diluent syringe filling, MedNet
for the vial adapter component, and PCI for diluent syringe packaging, the key terms of which are set out in an attachment to this letter. Schering and Chiron have agreed to share the incremental
costs of the diluent syringe under such agreements as follows: in the event Schering and Chiron sign a new agreement replacing the RFDS Agreement,  [***] Schering, [***]
 Chiron; in the event the parties
do not sign such a new agreement, Chiron's share will equal [***] and Schering's share shall  [***]. 

Please
sign the enclosed copy of this letter for our records. 

        Very
truly yours, 

        CHIRON
CORPORATION 

	By:	 	/s/  CRAIG WHEELER      
 Craig Wheeler

President, Chiron BioPharmaceuticals	 	 	 	 
	

Agreed:	
 	

 
	

SCHERING BERLIN, INC.	
 	

 
	

By:	
 	

/s/  WOLFGANG KUNZE      
	
 	

 	
 	

 
	 	 	[Signed copy shows strike-through of this name: Lutz Lingnau]

W. Kunze

EVP and CFO

QuickLinks

Exhibit 10.211QuickLinks
 -- Click here to rapidly navigate through this document
  

 
 

Exhibit 10.320    
  

	 
	 	 

	CONFIDENTIAL	 	REDACTED VERSION

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN

OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH

RESPECT TO THE OMITTED PORTIONS.  

 
  AMENDMENT NO. 4 TO
  AGREEMENT    
  

        This Amendment No. 4 ("Amendment No. 4") is entered effective March 5, 2003 (the
"Amendment Effective Date") pursuant to and amending that certain Agreement between Gen-Probe Incorporated, a Delaware corporation
("Gen-Probe") and Chiron Corporation, a Delaware corporation ("Chiron"). Capitalized terms
used but not defined herein shall have the meanings set forth in the Agreement. 

Recitals

        A.    The
parties entered into the Agreement as of June 11, 1998 pursuant to which, among other things, the parties described their respective rights and obligations
with respect to the development, manufacture, marketing and distribution of Products in the Blood Screening and Clinical Diagnostic Fields. The Agreement was amended by the following:
(i) June 11, 1998 Collaboration Agreement, (ii) June 11, 1998 Supplemental letter agreement, (iii) June 26, 1998 Addendum to Collaboration Agreement,
(iv) June 30, 1998 Supplemental letter agreement, (v) June 30, 1998 Consent, (vi) December 1, 1998 letter agreement re American Red Cross revenues,
(vii) December 7, 1999 Amendment, (viii) February 1, 2000 Second Amendment, (ix) June 7, 2001 Supplemental Agreement No. 1 (Customer training and
Support), (x) October 30, 2001 Confidentiality and Joint Interest Agreement, (xi) April 4, 2001 Agreement re Arbitration and (xii) April 1, 2002 Amendment
No. 3 (warehousing and shipping). In addition, the parties submitted a number of disputes under the Agreement to arbitration pursuant to Section 13 of the Agreement, and in resolution of
those disputes, executed a Definitive Written Settlement Agreement, dated December 5, 2001, and a Short Form Agreement, dated November 16, 2001. 

        B.    The
parties have previously revised Article 14 of the Agreement, memorialized in that certain December 7, 1999 Amendment. The parties have discussed a
further revision to and clarification of their respective rights and obligations with respect to Article 14, and have agreed to make certain additional changes to the Agreement in connection
therewith, in accordance with the provisions of this Amendment No. 4. 

Agreement

        NOW,
THEREFORE, for and in consideration of the mutual covenants and agreements set forth in this Amendment No. 4, the parties agree as follows: 

        1.    Ultrio on Tigris.    Article 14 of the Agreement shall be and is hereby amended
to read as follows: 

        "In
consideration for the rights originally granted to Chiron by this Agreement with respect to TMA and HPA, Chiron shall pay to Gen-Probe, or shall cause Bayer Corporation
to pay to Gen-Probe, the following nonrefundable amounts upon the occurrence of each event set forth below: 

        (1)  [**]  

         (2)  [**]  

         (3)  [**]  

1

 

         (4)  [**]  

        2.    No Other Amendment.    Except as is expressly set forth in
this
Amendment No. 4, all other terms and conditions of the Agreement shall continue in full force and effect. 

        3.    Counterparts.    This Amendment No. 4 may be executed in counterparts, each of
which shall be an original, and all of which together shall constitute one and the same instrument. 

2

 

        IN
WITNESS WHEREOF, the parties have caused this Amendment No. 4 to be executed and the persons signing below warrant that they are duly authorized to sign for and on behalf of
the respective parties. 

	Gen-Probe:	 	Chiron:
	

GEN-PROBE INCORPORATED,
 a Delaware corporation	
 	
CHIRON CORPORATION,
 a Delaware corporation
	

By: /s/ Henry L. Nordhoff

Its: President & Chief Executive Officer

Date: March 5, 2003	
 	

By: /s/ Jack Goldstein

Its: President, Chiron Blood Testing

Date: March 18, 2003

3

QuickLinks

Exhibit 10.320

AMENDMENT NO. 4 TO AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00051-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00051-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00051-of-00352.parquet"}]]